Informa Business Intelligence: While Over Three-Quarters of Americans Are Willing to Take at Least One of the Authorized COVID-19 Vaccines, Nearly a Quarter Are Still Hesitant as the U.S. Changes Course on Mitigation Strategy Understanding of Clinical Trials Up Among Americans Although vaccine hesitancy remains, levels of understanding have improved nearly two-fold following sentiments captured in Informa Pharma Intelligence's 2020 Pulse Reportwhen the COVID-19 vaccines had yet to be made available in the United States. 1 In fact, the percentage of Americans saying they'd be more likely to take a COVID-19 vaccine if they had more information on the clinical trials has dropped by half since 2020 (14% from 28%). Furthermore, the number of Americans saying they'd be more likely to participate in a clinical trial doubled from 7% in 2020 to 13% in 2021. This may show that Americans are far more versed on vaccine clinical trial data due to the U.S. government and vaccine makers communicating this information more effectively since fall 2020.